Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging

Gorodkiewicz,Ewa; Guszcz,Tomasz; Roszkowska‑Jakimiec,Wieslawa; Kozłowski,Robert

doi:10.3892/ol.2014.2250

Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging

Authors:
- Ewa Gorodkiewicz
- Tomasz Guszcz
- Wieslawa Roszkowska‑Jakimiec
- Robert Kozłowski
View Affiliations

Affiliations: Department of Electrochemistry, Institute of Chemistry, University of Bialystok, Bialystok PL‑15‑443, Poland, Department of Urology, J. Sniadecki Provincial Hospital of Bialystok, Bialystok PL‑15‑950, Poland, Department of Analytical Chemistry, Medical University of Bialystok, Bialystok PL‑15‑230, Poland
Published online on: June 12, 2014 https://doi.org/10.3892/ol.2014.2250
Pages: 1323-1327

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Determination of cathepsin D (Cat D) concentration in serum and urine may be useful in the diagnosis of bladder cancer. The present study included 54 healthy patients and 68 patients with bladder cancer, confirmed by transurethral resection or cystectomy. Cat D concentration was determined using a surface plasmon resonance imaging biosensor. Cat D concentration in the serum of bladder cancer patients was within the range of 1.3‑5.59 ng/ml, while for healthy donors it was within the range of 0.28‑0.52 ng/ml. In urine, the Cat D concentration of bladder cancer patients was within the range of 1.35‑7.14 ng/ml, while for healthy donors it was within the range of 0.32‑0.68 ng/ml. Cat D concentration may represent an efficient tumor marker, as its concentration in the serum and urine of transitional cell carcinoma patients is extremely high when compared with healthy subjects.

View Figures

View References

1	Faust PL, Kornfeld S and Chirgwin JM: Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci USA. 82:4910–4914. 1985.
2	Barrett AJ and Cathepsin D: Purification of isoenzymes from human and chicken liver. Biochem J. 117:601–607. 1970.
3	Têtu B, Brisson J, Côté C, et al: Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer. 55:429–435. 1993.
4	Veneroni S, Daidone MG, Di Fronzo C, et al: Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Res Treat. 26:7–13. 1993.
5	Métayé T, Millet C, Kraims JL, et al: Estrogen receptors and cathepsin D in human thyroid tissue. Cancer. 72:1991–1996. 1993.
6	Warwas M and Taurowska E: Cathepsin D in diagnosis of neoplastic diseases. Postepy Hig Med Dosw. 47:277–288. 1993.(In Polish).
7	Ferlay J, Shin HR, Bray F, et al: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer. GLOBOCAN; Lyon, France: 2008, http://globocan.iarc.fr. Accessed 4 July, 2010
8	Burger M, Catto JW, Dalbagni G, et al: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241. 2013.
9	Fernández-González A, Rychłowska J, Badía R and Salzer R: SPR imaging as a tool for detecting mucin - anti-mucin interaction. Outline of the development of a sensor for near-patient testing for mucin. Microchim Acta. 158:219–225. 2007.
10	Lee HJ, Nedelkov D and Corn RM: Surface plasmon resonance imaging measurements of antibody arrays for the multiplexed detection of low molecular weight protein biomarkers. Anal Chem. 78:6504–6510. 2006.
11	Gorodkiewicz E, Regulska E and Roszkowska-Jakimiec W: Determination of the active form concentration of cathepsins D and B by SPRI biosensors. J Lab Diagn. 46:107–109. 2010.
12	Gorodkiewicz E and Regulska E: SPR imaging biosensor for aspartyl cathepsins: sensor development and application for biological material. Protein Pept Lett. 17:1148–1154. 2010.
13	Gorodkiewicz E, Regulska E and Wojtulewski K: Development of an SPR imaging biosensor for determination of cathepsin G in saliva and white blood cells. Mikrochim Acta. 173:407–413. 2011.
14	Gorodkiewicz E, Ostrowska H and Sankiewicz A: SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma. Microchim Acta. 175:177–184. 2011.
15	Gorodkiewicz E, Charkiewicz R, Rakowska A, et al: SPR imaging biosensor for podoplanin: sensor development and application to biological materials. Microchim Acta. 176:337–343. 2012.
16	Gorodkiewicz E: Surface Plasmon Resonance Imaging sensor for cathepsin determination based on immobilized cystatin. Protein Pept Lett. 16:1379–1385. 2009.
17	Tokyol C, Köken T, Demirbas M, et al: Expression of cathepsin D in bladder carcinoma: correlation with pathological features and serum cystatin C levels. Tumori. 92:230–235. 2006.
18	Salman T, el-Ahmady O, el-Shafee M, et al: Cathepsin-D and TNF-alpha in bladder cancer. Dis Markers. 12:253–259. 1996.
19	Kotaska K, Dusek P, Prusa R, et al: Urine and serum cathepsin B concentration in the transitional cell carcinoma of the bladder. J Clin Lab Anal. 26:61–65. 2012.
20	Szajda SD, Darewicz B, Kudelski J, et al: Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer. Pol Merkur Lekarski. 18(108): 651–653. 2005.
21	Herr HW: Transuretheral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 19:89–93. 2001.
22	European Association of Urology. Non-muscle-invasive (Ta, T1 and CIS) bladder cancer. http://www.uroweb.org/guidelines/online-guidelines/. Accessed March 13, 2012
23	American Urological Association. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1 and Tis): Update 2007. http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm. Accessed November 15, 2007
24	Elissa S, Swellam M, Sadek M, et al: Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of the bladder tumors. J Urol. 168:465–469. 2002.
25	Menéndez V, Fernández-Suárez A, Galán JA, et al: Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology. 65:284–289. 2005.
26	Lotan Y, Shariat SF, Schmitz-Dräger BJ, et al: Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 28:441–448. 2010.
27	Catto JWF: Old and new urinary markers: Which one is the PSA for bladder cancer? Eur Urol Suppl. 7:422–425. 2008.